ICH E17

General principle on planning and design of Multi-Regional Clinical Trials

January 14th, 2017

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

Legal Notice

This presentation is protected by copyright and may be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the presentation is acknowledged at all times. In case of any adaption, modification or translation of the presentation, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original presentation. Any impression that the adaption, modification or translation of the original presentation is endorsed or sponsored by the ICH must be avoided.

The presentation is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original presentation be liable for any claim, damages or other liability arising from the use of the presentation.

The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.
ICH HARMONISED TRIPARTITE GUIDELINE

General Principles for Planning and Design of Multi-Regional Clinical Trials
E17 (FINAL)

November 16th, 2017

ICH E17 Guideline
- Started in June 2014
- Draft in June 2016
- Finalised in November 2017

Table of Contents (E17 final)

1. INTRODUCTION .................................................................................. 1
   1.1 Objectives of the Guideline ....................................................... 1
   1.2 Background .............................................................................. 1
   1.3 Scope of the Guideline ............................................................. 2
   1.4 Basic Principles ...................................................................... 2
2. GENERAL RECOMMENDATIONS IN THE PLANNING AND DESIGN OF MRCTS ................................................................. 3
   2.1 Strategy-related Issues .............................................................. 3
      2.1.1 The Value of MRCTs in Drug Development ..................... 3
      2.1.2 Good Clinical Practice (GCP) Requirements and MRCTs 6
      2.1.3 Scientific Consultation Meetings with Regulatory Authorities 6
   2.2 Clinical Trial Design and Protocol-related Issues .................. 7
      2.2.1 Pre-consideration of Regional Variability and its Potential Impact on Efficacy and Safety 7
      2.2.2 Subject Selection ............................................................... 9
      2.2.3 Selection of Doses for Use in Confirmatory MRCTs .......... 10
      2.2.4 Choice of Endpoints ....................................................... 11
      2.2.5 Sample Size Planning ..................................................... 13
      2.2.6 Collecting and Handling of Efficacy and Safety Information 18
      2.2.7 Statistical Analysis Planning ......................................... 20
      2.2.8 Selection of Comparators ............................................. 23
      2.2.9 Handling Concomitant Medications ................................ 25
3. GLOSSARY ....................................................................................... 26
1.1 Objectives of the Guideline

• With the increasing globalisation of drug development, it has become important that data from multi-regional clinical trials (MRCTs) can be accepted by regulatory authorities across regions and countries as the primary source of evidence, to support marketing approval of drugs (medicinal products).

• The purpose of this guideline is to describe general principles for the planning and design of MRCTs with the aim of increasing the acceptability of MRCTs in global regulatory submissions.

• The guideline addresses strategic programme issues as well as issues that are specific to the planning and design of confirmatory MRCTs, and it should be used together with other ICH Guidelines, including E5, E6, E8, E9, E10, and E18.

1.3 Scope of the Guideline

• MRCT is defined in the present guideline as a clinical trial conducted in more than one region under a single protocol. In this context, a region may refer to a geographical region, country or regulatory region (see Section 3. Glossary).

• The primary focus of this guideline is on MRCTs designed to provide data that will be submitted to multiple regulatory authorities for drug approval (including approval of additional indications, new formulations and new dosing regimens) and for studies conducted to satisfy post-marketing requirements.

• Certain aspects of this guideline may also be relevant to studies conducted early in clinical development or in later phases. The present guideline mainly covers drugs including biological products, although some sections may not be applicable to all development programmes (e.g., pharmacokinetics (PK) not used for preventive vaccine dose-finding).
2.1.1 The Value of MRCTs in Drug Development

1. Independent strategy: Local trials
   - A region
     - PK Exploratory clinical trials
     - PK Confirmatory clinical trials
     - Regulatory Review
   - B region
     - PK Exploratory clinical trials
     - PK Confirmatory clinical trials
     - Regulatory Review

2. Global strategy: representative example of MRCTs
   - A region
     - Exploratory clinical trials ** including pharmacology (PK/PD) study
     - Multi Regional Confirmatory Clinical Trials
     - Regulatory Review
   - B region
     - No delay

Figure 1: Illustration of clinical drug development workflow across regions for drug registration and regulatory review in independent and global strategies.

** Denotes interaction/registration for Drug Application
** Denotes parallel type of trials at MRCTs

1.4 Basic Principles
1.4 Basic Principles (1)

1. Strategic use of MRCTs in drug development programmes, properly designed and executed according to this guideline, can increase efficiency of drug development. MRCTs may enable simultaneous submission of marketing authorisation applications and support regulatory decision-making in multiple regions, allowing earlier access to new drugs worldwide. Although MRCTs may generally become the preferred option for investigating a new drug for which regulatory submission is planned in multiple regions, the potential for regional differences to impact the interpretability of study results should be carefully considered.

2. The intrinsic and extrinsic factors important to the drug development programme, should be identified early. The potential impact of these factors could be examined in the exploratory phases before the design of confirmatory MRCTs. Information about them should also be collected during the confirmatory trial for evaluation of their impact on treatment effects.

1.4 Basic Principles (2)

3. MRCTs are planned under the assumption that the treatment effect applies to the entire target population, particularly to the regions included in the trial. Strategic allocation of the sample size to regions allows an evaluation of the extent to which this assumption holds.

4. Pre-specified pooling of regions or subpopulations, based on established knowledge about similarities, may help provide flexibility in sample size allocation to regions, facilitate the assessment of consistency in treatment effects across regions, and support regulatory decision-making.

5. A single primary analysis approach for hypothesis testing and estimation of the overall treatment effect should be planned so that it will be acceptable to all concerned regulatory authorities. A structured exploration to examine the consistency of treatment effects across regions and subpopulations should be planned.
6. In light of diverse regional practices, **ensuring high quality** of study design and conduct in accordance with ICH E6 in all regions is of paramount importance to ensure the study results are interpretable. Careful attention to quality during trial planning, investigator training, and trial monitoring will help achieve consistently high trial quality required for a successful MRCT.

7. **Efficient communication** among sponsors and regulatory authorities is encouraged at the planning stage of MRCTs, with the goal of obtaining acceptance of a global approach to study design across the different regulatory regions.

Major points described in Section 2
2.2.1 Pre-consideration of Regional Variability and its Potential Impact on Efficacy and Safety

- At the planning stage, regional variability, the extent to which it can be explained by intrinsic and extrinsic factors, and its potential to influence the study results, should be carefully considered in determining the role MRCTs can play in the drug development strategy.

- The intrinsic and extrinsic factors important to the drug development programme, should be identified during the planning stage of an MRCT.

Figure 2 illustrates the way in which intrinsic and/or extrinsic factors such as disease severity (Figure 2a) or ethnicity (Figure 2b) may manifest as regional differences in treatment response.
2.2.2 Subject Selection

- In MRCTs, subject selection should be carefully considered to better understand and possibly mitigate potential sources of regional variability and their impact on trial results.

- Clear and specific inclusion and exclusion criteria, that are acceptable and can be applied across regions, should be included in the protocol.

- To harmonise subject selection, uniform classification and criteria for diagnosis of the disease or definition of the at-risk population should be implemented, such as the use of relevant guidelines for disease definitions.

2.2.3 Selection of Doses for Use in Confirmatory MRCTs

- It is important to execute well-planned early development programmes that include PK and/or PK-PD studies of applicable parameters, in order to identify regional differences which may impact dose selection.

- The dose regimens in confirmatory MRCTs (based on data from studies mentioned above) should in principle be the same in all participating ethnic population.

- If earlier trial data show a clear difference in dose-response and/or exposure-response relationships for an ethnic population, it may be appropriate to use a different dosing regimen, provided that the regimen is expected to produce similar therapeutic effects with an acceptable safety margin, and provided it is scientifically justified in the study protocol. Prospective careful planning of assessment strategies where different doses are used should be tailored to each case and described in the analysis plans.
2.2.4 Choice of Endpoints

- The primary endpoint should be relevant to the target population. In MRCTs, this relevance needs to be considered for all regions in the trial and with respect to the various drug, disease and population characteristics represented in those regions.

- An ideal clinical trial endpoint is one that is clinically relevant, accepted in medical practice (e.g., by regulatory guidance or professional society guidelines) and sufficiently sensitive and specific to detect the anticipated effect of the treatment.

- The primary endpoint, whether efficacy or safety, should satisfy these criteria as well as being acceptable to all concerned regulatory authorities, to ensure that interpretation of the success or failure of the MRCT is consistent across regions and among regulatory authorities.

- The primary endpoint of MRCTs should be one for which experience is already available in the participating regions.

2.2.5 Sample Size Planning

- The key consideration for sample size planning is ensuring sufficient sample size to be able to evaluate the overall treatment effect, under the assumption that the treatment effect applies to the entire target population, particularly to the regions included in the trial.

- Two additional factors are particularly important in the MRCT setting: (i) the size of the treatment effect that is considered clinically relevant to all regions in the trial, and (ii) the expected variability of the primary outcome variables based on combining data across regions.
The MRCT should be planned to include an evaluation of the consistency of treatment effects among regions, where consistency is defined as a lack of clinically relevant differences.

If clinically relevant differences among regions are observed, then the MRCT provides a unique opportunity for additional learning about the factors that may explain these differences.

Regional allocation should have a scientific basis (rather than arbitrary targets), should support the evaluation of consistency and should provide the information needed to support regulatory decisions.

2.2.5 Sample Size Planning

Five examples for sample size allocation to region:

1. Proportional Allocation: Allocation of subjects to regions in proportion to size of region and disease prevalence.
2. Equal Allocation: Allocation of equal numbers of subjects to each region.
3. Preservation of Effect: Allocation of subjects to one or more regions based on preserving some specified proportion of the overall treatment effect.
4. Local Significance: Allocation of a sufficient number of subjects to be able to achieve significant results within each region.
5. Fixed Minimum Number: Allocation of a fixed minimum number of subjects to a region.

A balance between #1 and #2 is recommended to ensure that recruitment is feasible and able to be completed in a timely fashion, but also to provide sufficient information to evaluate the drug in its regional context.
Pooled Regions and Subpopulations

• Pooled regions:
  Pooling some geographical regions, countries or regulatory regions at the planning stage, if subjects in those regions are thought to be similar enough with respect to intrinsic and/or extrinsic factors relevant to the disease and/or drug under study.

• Pooled subpopulations:
  Pooling a subset of the subjects from a particular region with similarly defined subsets from other regions whose members share one or more intrinsic or extrinsic factors important for the drug development programme at the planning stage. Pooled subpopulations is assumed as ethnicity-related subgroup particular important in the MRCT setting.

• Pre-specified pooling of regions or subpopulations may help provide flexibility in sample size allocation to regions, facilitate the assessment of consistency in treatment effects across regions, and support regulatory decision-making.

• The pooling strategy should be justified based on the distribution of the intrinsic and extrinsic factors known to affect the treatment response, and the disease under investigation and similarity of those factors across regions.
  - For example, pooling Canada and the United States into a North American region is often justified because of similar medical practices and similar use of concomitant medications.

• Pooling strategies should be specified in the study protocol and statistical analysis plan, if applicable.
2.2.6 Collecting and Handling of Efficacy and Safety Information

- Adherence to GCP is critical for any clinical trial to meet its stated objectives and is particularly important in an MRCT, because of the coordination required to conduct a trial in diverse geographic regions.

- Methods of collecting and handling efficacy and safety information should be standardised across participating regions.

- It is also important to provide standardised training for investigators and study personnel in each region before initiating the trial in that region to ensure that the trial objectives are met through standardised implementation of the study protocol.

2.2.7 Statistical Analysis Planning

- The analysis strategy should be planned to enable the qualitative and/or quantitative evaluation of benefit/risk across regions or important subpopulations represented in the MRCT.

- In planning an MRCT, the primary analysis strategy should carefully consider
  1. the target population,
  2. the endpoints/variables of primary interest
  3. the relevant intrinsic and extrinsic factors in the multi-regional, multi-subpopulation context
  4. the population-level summary of data required to describe the treatment effect.

- For most MRCTs, the primary analysis will correspond to a test of the hypothesis about the treatment effect and the estimation of that effect, considering data from all regions and subpopulations included in the trial.
2.2.7. Statistical Analysis Planning

The statistical analysis strategy should include the evaluation of the consistency of treatment effects across regions and subpopulations.

The evaluation of regional consistency is not considered a confirmatory exercise but rather a gateway for further exploration.

2.2.7. Statistical Analysis Planning

- In case of clinically relevant differences in treatment effects among regions, a structured exploration of these differences should be planned.
  - Factors known a priori to vary among regions (e.g., disease severity, race, other subject characteristics) and hypothesized to be **prognostic or predictive** should be planned for and evaluated in the analysis model.
  - Unexpected regional differences may be observed, and post-hoc analyses should be used for further investigation. Factors known to be prognostic for the disease would be examined first.
  - Regional differences may require further post-hoc investigation to either identify plausible reasons for the differences or to better understand the observed heterogeneity. In some cases, additional data, including data from other clinical trials, or supportive evidence from other sources, may be needed to understand the regional differences observed.
  - These eventualities should be carefully considered at the planning stage.
2.2.8. Selection of Comparators

- The choice of control groups should be considered in the context of the available standard therapies, the adequacy of the evidence to support the chosen design, and ethical considerations.
- Comparators in MRCTs should in principle be the same in all participating regions.
- The justification (including safety considerations) for the use of an unapproved drug should therefore be described in the protocol based on scientific information, treatment guidelines and other relevant documents.

2.2.9. Handling Concomitant Medications

- In general, drugs used concomitantly with the investigational drug should be the same throughout the regions to the extent possible, but there may be some differences in the drugs and/or doses actually used due to variations in medical practices. This could be acceptable if not expected to substantially impact trial results.
- In circumstances where approved drugs are combined with an investigational drug, the same dosage regimen in all regions should generally be applied.
- If required by protocol, concomitant medications that are not approved in a region should have their use justified based on scientific information, treatment guidelines and other relevant documents.
Impacts of E17 guideline

• Earlier access to innovative therapies
  o Synchronize clinical drug development across different regions

• Avoid duplication
  o Reduce the need for region specific studies and bridging studies

• Promote international harmonization
  o A globally harmonized approach to drug development should be considered first

• Provide better evidences for drug approval in each region
  o Incorporate latest knowledge and experience from regions into one trial

• Develop an infrastructure for global drug development
  o Conducting high quality MRCTs is a valuable investment in modern drug development

Thank You!